write a note on management of gout briefly ( 1 page)

Reading File

Finding Sources

Reading File

I now have comprehensive information to write the note. Let me compile it:

Management of Gout

Overview

Gout is a crystal deposition arthritis caused by monosodium urate (MSU) precipitation in joints and soft tissues, driven by sustained hyperuricemia. Management targets three goals: (1) relief of the acute attack, (2) prevention of recurrence, and (3) long-term lowering of serum urate.

1. Management of Acute Gouty Attack

NSAIDs (first-line) Full-dose NSAIDs started as early as possible are the treatment of choice. Indomethacin (50 mg TID) is classical, but any NSAID at maximum therapeutic dose is effective. After 2 days at peak dose, taper over the next few weeks. Avoid in renal impairment, peptic ulcer disease, and in patients on anticoagulants.

Colchicine (second-line) Colchicine inhibits neutrophil recruitment and NLRP3 inflammasome activation, reducing IL-1β release. It relieves most acute attacks within 6-12 hours. Low-dose regimen: 1.2 mg initially, then 0.6 mg 1 hour later (total 1.8 mg). High GI side effects (nausea, vomiting, diarrhea) limit its use. Contraindicated in significant hepatic or renal impairment. Interacts with CYP3A4 and P-glycoprotein inhibitors (e.g., clarithromycin, cyclosporine).

Corticosteroids (when NSAIDs/colchicine contraindicated)

Oral: Prednisone 0.5 mg/kg/day, tapered by 5 mg/day
Intra-articular: Triamcinolone 10-40 mg (large joints), 5-20 mg (small joints) - preferred for monoarticular attacks
ACTH 40-80 mg IM/IV every 8-12 h can be used when all else fails

2. Prophylaxis of Recurrent Attacks

After the first attack resolves, low-dose colchicine (0.5-0.6 mg once or twice daily) or low-dose NSAIDs are used as bridging prophylaxis when initiating urate-lowering therapy (ULT), as starting ULT can precipitate a flare. Prophylaxis is continued for at least 3-6 months.

Lifestyle modification runs alongside pharmacotherapy: reduce alcohol (especially beer), avoid purine-rich foods (red meat, organ meats, shellfish), increase hydration, lose weight, and avoid fructose-containing beverages.

3. Urate-Lowering Therapy (ULT)

Indications: Two or more attacks per year, tophi, chronic gouty arthropathy, uric acid nephrolithiasis, or urate nephropathy.

Target serum uric acid: < 6 mg/dL (< 5 mg/dL in tophaceous gout).

Xanthine Oxidase Inhibitors (first-line ULT)

Drug	Dose	Notes
Allopurinol	100 mg/day initially; titrate to 300-800 mg/day	Adjust for renal function; risk of allopurinol hypersensitivity syndrome (AHS) - rare but severe (SJS/TEN); screen HLA-B*5801 in high-risk populations (Han Chinese, Korean, Thai)
Febuxostat	40-80 mg/day	Non-purine analogue; preferred in allopurinol intolerance; caution in cardiovascular disease (higher CV mortality vs. allopurinol in CARES trial)

Uricosuric Agents (second-line or add-on)

Probenecid (500 mg BD, titrate to 1-2 g/day): blocks URAT-1 renal transporter; ineffective in renal impairment (GFR < 30); avoid in nephrolithiasis; maintain high fluid intake
Benzbromarone: more potent uricosuric; available in some countries

Recombinant Uricases (refractory tophaceous gout)

Pegloticase (IV infusion every 2 weeks): converts urate to allantoin; reserved for severe refractory gout; risk of infusion reactions and immunogenicity
Rasburicase: used mainly for tumor lysis syndrome

4. Special Situations

Transplant recipients / diuretic users: Losartan (uricosuric) and fenofibrate have off-label urate-lowering effects and can be chosen preferentially in relevant comorbidities
Asymptomatic hyperuricemia: Treatment is generally NOT recommended due to cost and toxicity
Renal impairment: Allopurinol dose must be adjusted; probenecid is ineffective; febuxostat may be used with caution
Refractory / biologic therapy: Canakinumab (anti-IL-1β monoclonal antibody) is EMA-approved when conventional agents fail or are contraindicated; not FDA-approved for gout

Summary Algorithm

Acute attack
   └─ NSAIDs (1st line) → Colchicine (2nd line) → Corticosteroids (3rd line)

After attack resolves + indications for ULT
   └─ Start colchicine prophylaxis (0.5 mg BD)
   └─ Initiate allopurinol (titrate to target uric acid < 6 mg/dL)
   └─ Continue prophylaxis for 3-6 months
   └─ Lifestyle modification throughout

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Textbook of Family Medicine 9e; Goldman-Cecil Medicine

drug profile on Semaglutide

Reading File

Finding Sources

Searching PubMed

semaglutide cardiovascular outcomes obesity diabetes

Finding Sources

Reading File

Excellent - I now have comprehensive information from multiple authoritative textbooks plus recent PubMed evidence. Let me compile the full drug profile:

Drug Profile: Semaglutide

1. Basic Classification

Property	Detail
Drug class	Glucagon-like peptide-1 (GLP-1) receptor agonist
Type	Long-acting synthetic GLP-1 analog
Pronunciation	sem-a-GLOO-tide
Trade names	Ozempic (diabetes, SC), Rybelsus (diabetes, oral), Wegovy (obesity, SC)
FDA approvals	Type 2 diabetes mellitus; Chronic weight management (obesity); CV risk reduction in T2DM with established CVD

2. Mechanism of Action

Semaglutide is a synthetic agonist at the GLP-1 receptor that is structurally modified to resist rapid enzymatic degradation (the major limitation of native GLP-1, which has a very short half-life). It acts via multiple complementary mechanisms:

Glucose-dependent insulin secretion: Stimulates pancreatic beta cells to release insulin only in the presence of elevated glucose - minimal hypoglycemia risk as a monotherapy
Glucagon suppression: Reduces postprandial glucagon secretion, limiting hepatic glucose output
Gastric emptying delay: Slows gastric motility, blunting postprandial glucose spikes
Satiety and appetite reduction: Acts on hypothalamic GLP-1 receptors and vagal afferents to enhance satiety signals and reduce hunger, leading to decreased caloric intake and weight loss
Beta-cell proliferation: Promotes beta-cell growth and may preserve beta-cell mass

The incretin effect (oral glucose eliciting 60-70% more insulin than IV glucose) is markedly reduced in type 2 diabetes, and GLP-1 receptor agonists partially restore this physiological response.

3. Pharmacokinetics

Parameter	SC Semaglutide	Oral Semaglutide
Route	Subcutaneous injection	Oral tablet
Dosing frequency	Once weekly	Once daily
Bioavailability	High (SC)	~1% (enhanced with absorption enhancer SNAC)
Half-life	~1 week	~1 week
Protein binding	>99% (albumin)
Metabolism	Proteolytic cleavage; no specific organ of elimination	Similar
Excretion	Urine and feces as metabolites
Dose adjustment	No dose adjustment required for mild-moderate renal or hepatic impairment

Oral semaglutide must be taken on an empty stomach with a small amount of plain water (up to 120 mL), and the patient must wait at least 30 minutes before eating or taking other medications - the absorption enhancer sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) facilitates gastric absorption.

4. Indications & Approved Doses

Type 2 Diabetes (Ozempic SC / Rybelsus oral)

SC: Start 0.25 mg SC once weekly x 4 weeks → 0.5 mg once weekly; may increase to 1 mg or 2 mg based on glycemic response
Oral: Start 3 mg once daily x 30 days → 7 mg once daily; may increase to 14 mg once daily
Also reduces risk of major adverse cardiovascular events (MACE) in T2DM patients with established CVD

Obesity / Chronic Weight Management (Wegovy SC)

Start 0.25 mg once weekly → titrate every 4 weeks: 0.5 → 1.0 → 1.7 → 2.4 mg once weekly (maintenance)
Indicated for BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity

Cardiovascular Risk Reduction (SELECT trial - without diabetes)

2.4 mg SC once weekly approved to reduce CV events in adults with obesity/overweight and established CVD but without T2DM

5. Clinical Efficacy

HbA1c reduction: ~1.5-1.8% reduction (T2DM)
Weight loss: 10-15% body weight reduction at 2.4 mg dose (STEP trials); up to 15-17% in STEP 1 trial
Cardiovascular outcomes (SUSTAIN-6 trial): 26% relative risk reduction in MACE (CV death, non-fatal MI, non-fatal stroke) vs placebo in T2DM
SELECT trial (2023): 20% reduction in MACE in obese/overweight patients without diabetes
A 2025 systematic review and meta-analysis (PMID: 39396098) confirmed semaglutide's cardiovascular safety benefits in overweight/obese patients

6. Adverse Effects

Common (GI - most frequent, usually transient)

Nausea, vomiting, diarrhea, constipation
Occur mostly during dose escalation; tend to resolve over weeks

Serious / Clinically Important

Adverse Effect	Notes
Pancreatitis	Rare; discontinue if suspected; contraindicated in history of pancreatitis
Gallbladder disease	Cholelithiasis, cholecystitis (rapid weight loss risk)
Thyroid C-cell tumors	Seen in rodents at high doses; risk in humans unknown; contraindicated in MEN2 or personal/family history of medullary thyroid carcinoma (MTC)
Diabetic retinopathy	Worsening reported with rapid HbA1c reduction (SUSTAIN-6); a 2025 meta-analysis (PMID: 40810985) highlighted ocular adverse events
Hypoglycemia	Low risk as monotherapy; risk increases with insulin or sulfonylurea combination
Acute kidney injury	Typically from dehydration secondary to severe GI effects
Tachycardia	Modest increase in resting heart rate (~2-4 bpm)
Suicidal ideation	Noted in prescribing information; monitor for mood changes

7. Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple endocrine neoplasia type 2 (MEN2)
History of serious hypersensitivity to semaglutide
Pregnancy (discontinue at least 2 months before planned pregnancy)
Chronic pancreatitis (relative contraindication)

8. Drug Interactions

Interacting Drug	Mechanism	Clinical Significance
Insulin / sulfonylureas	Additive glucose lowering	Reduce insulin/SU dose; hypoglycemia risk
Oral medications	Delayed gastric emptying	Absorption of co-administered oral drugs may be slowed; separate timing of critical drugs (e.g., levothyroxine, oral contraceptives)
Warfarin	Delayed absorption of warfarin	Monitor INR closely when initiating or changing semaglutide dose

9. Special Populations

Population	Recommendation
Renal impairment	No dose adjustment needed; monitor for dehydration-related AKI
Hepatic impairment	Use with caution; limited data
Elderly	No dose adjustment required; greater caution for GI effects and dehydration
Pregnancy	Contraindicated; potential fetal harm
Breastfeeding	Not recommended; excretion in human milk unknown
Pediatrics	Ozempic approved ≥ 12 years for T2DM; Wegovy approved ≥ 12 years for obesity
Post-bariatric surgery	May provide additional weight loss benefit as adjuvant therapy

10. Place in Therapy

Diabetes: After metformin (or as first-line in patients with established ASCVD, heart failure, or CKD per ADA guidelines). Preferred over DPP-4 inhibitors and SGLT2 inhibitors when weight loss is a priority.

Obesity: First-line pharmacotherapy for eligible patients (BMI ≥ 30 or ≥ 27 with comorbidities) alongside lifestyle modification. The most efficacious single-agent anti-obesity drug currently available.

Cardiovascular protection: Now indicated for CV risk reduction independent of glycemic control, representing a paradigm shift in its use beyond metabolic disease.

11. Monitoring Parameters

HbA1c every 3 months (until stable, then every 6 months)
Fasting blood glucose (self-monitoring)
Body weight and BMI
Renal function (especially if GI side effects are severe)
Thyroid examination / calcitonin if clinically indicated
Signs/symptoms of pancreatitis
Ophthalmology review in diabetic patients at baseline and after rapid HbA1c drops

Sources: Lippincott Illustrated Reviews Pharmacology; Katzung's Basic & Clinical Pharmacology 16e; Goldman-Cecil Medicine; Neuroscience: Exploring the Brain 5e. Recent evidence: PMID 39396098 (Syst. Rev., Int J Obes 2025); PMID 40810985 (Meta-Analysis, JAMA Ophthalmol 2025)

note on leukemoid reaction briefly

Finding Sources

Reading File

Loading Image

Reading File

Excellent - I have comprehensive content from Henry's Clinical Diagnosis, Goldman-Cecil Medicine, and the peripheral blood smear image. Here is the complete note:

Leukemoid Reaction

Definition

A leukemoid reaction is an excessive leukocytic response in the peripheral blood that mimics leukemia morphologically but is due to a benign reactive cause. It is defined as a white blood cell count ≥ 50 × 10⁹/L (50,000/μL) with a pronounced left shift - the appearance of immature precursor cells in the peripheral circulation.

Peripheral Blood Smear

Peripheral blood smear of a leukemoid reaction - morphologically indistinguishable from CML; distinction requires BCR-ABL testing (Goldman-Cecil Medicine)

Types

Leukemoid reactions are classified by the predominant cell type:

Type	Predominant Cell	Common Causes
Neutrophilic (most common)	Mature + immature neutrophils	Sepsis (TB, C. difficile), burns, hemorrhage, hemolysis, malignancy with bone marrow involvement, Hodgkin lymphoma, eclampsia, toxins
Lymphocytic	Lymphocytes	Infectious lymphocytosis, pertussis (whooping cough), infectious mononucleosis
Eosinophilic	Eosinophils	Parasitic infections (common in children)
Monocytic	Monocytes	Chronic infections, collagen vascular disease

Pathophysiology

In response to severe physiological stress - infection, inflammation, tissue necrosis, malignancy, or toxins - massive cytokine release (G-CSF, GM-CSF, IL-1, IL-6, TNF-α) drives extreme marrow stimulation. The marrow releases not just mature neutrophils but also immature precursors (bands, metamyelocytes, myelocytes) into the circulation, producing the "left shift."

Blood Film Features (Neutrophilic Type)

Leukocytosis > 50 × 10⁹/L
Pronounced left shift: bands, metamyelocytes, myelocytes in circulation
Toxic granulation (dark, coarse cytoplasmic granules in neutrophils)
Döhle bodies (pale blue cytoplasmic inclusions)
Cytoplasmic vacuoles in neutrophils
No basophilia or eosinophilia (contrast with CML)
No anemia or thrombocytosis as a primary finding

Leukemoid Reaction vs. CML - Key Differences

Feature	Leukemoid Reaction	CML
Cause	Reactive (infection, malignancy, etc.)	Clonal myeloproliferative neoplasm
WBC	Often > 50 × 10⁹/L	Often > 100 × 10⁹/L
Left shift	Present (bands, metas, myelocytes)	Present - "myelocyte peak" characteristic
Basophilia	Absent	Present (hallmark feature)
Eosinophilia	Absent	Present
Panmyelosis	Absent	Present (all cell lines increased)
Toxic granulation / Döhle bodies	Present	Absent
NAP/LAP score	Normal or elevated	Decreased (key distinguishing test)
BCR-ABL	Negative	Positive (diagnostic)
Philadelphia chromosome	Absent	Present (t(9;22))
Splenomegaly	Absent or mild	Common, often massive
Bone marrow	Reactive hyperplasia only	Hypercellular with all myeloid series

NAP = Neutrophil Alkaline Phosphatase - the single most important bedside differentiating test before BCR-ABL is sent.

Leukoerythroblastic Reaction

A special variant where circulating normoblasts (nucleated red cells) accompany a neutrophilic leukemoid reaction. This "leukoerythroblastic picture" is seen in:

Metastatic carcinoma infiltrating bone marrow
Myelofibrosis
Marrow infection or granulomatous disease
Benign conditions: severe GI bleeding, hemolytic anemia

Diagnosis Workup

Clinical history - look for identifiable cause (infection, malignancy, drugs, burns)
Peripheral smear - toxic changes confirm reactive nature
NAP/LAP score - elevated = leukemoid reaction; reduced = CML
CRP / ESR / Procalcitonin - elevated in reactive states
BCR-ABL by PCR or FISH - definitive exclusion of CML
Bone marrow biopsy - if no cause identified, to exclude myeloproliferative disease, infiltration, or fibrosis
Specific investigations based on suspected cause (blood cultures, TB workup, tumor markers, etc.)

Management

Leukemoid reaction itself requires no specific treatment. Management is directed at the underlying cause:

Severe infections - appropriate antimicrobial therapy
Underlying malignancy - oncology referral
Hemolysis/hemorrhage - treat the cause
The leukocytosis resolves once the trigger is removed

Sources: Henry's Clinical Diagnosis and Management by Laboratory Methods; Goldman-Cecil Medicine International Edition; Textbook of Family Medicine 9e

drug profile on pembrolizumab

Finding Sources

Searching PubMed

pembrolizumab cancer immunotherapy outcomes

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive information from authoritative sources. Here is the full drug profile:

Drug Profile: Pembrolizumab

1. Basic Classification

Property	Detail
Drug class	Immune checkpoint inhibitor - anti-PD-1 monoclonal antibody
Type	Humanized monoclonal IgG4κ antibody
Former names	Lambrolizumab; MK-3475
Trade name	Keytruda
Route	Intravenous infusion only
Developer	Merck; first FDA approval 2014 (melanoma)

2. Mechanism of Action

Mechanism of immune checkpoint inhibitors showing pembrolizumab blocking PD-1 on T lymphocytes

Fig: Pembrolizumab and nivolumab block PD-1 on T lymphocytes; atezolizumab/avelumab block PD-L1 on tumor cells; ipilimumab blocks CTLA-4 (Lippincott Illustrated Reviews Pharmacology)

Normal physiology: T-cell activation requires two signals - (1) TCR binding to MHC-peptide on an antigen-presenting cell, and (2) CD28 costimulatory binding to B7 proteins. After activation, T cells upregulate inhibitory receptors including PD-1 (Programmed Death-1) to prevent autoimmune collateral damage. Binding of PD-1 to its ligands PD-L1 or PD-L2 induces T-cell exhaustion and terminates the immune response.

Cancer exploitation: Tumor cells and tumor-infiltrating macrophages upregulate PD-L1, presenting it to tumor-infiltrating T cells to shield themselves from cytotoxic T-cell killing - an "immune escape" mechanism.

Pembrolizumab's action: It is a humanized antibody with a mouse variable region grafted onto a human IgG4 framework, showing high affinity for PD-1 on human and primate T cells. By blocking PD-1 from binding PD-L1/PD-L2, pembrolizumab:

Restores and sustains T-cell antitumor cytotoxic activity
Increases production of TNF-α, IFN-γ, and granzyme B
Prevents T-cell exhaustion within the tumor microenvironment
Allows immune-mediated eradication of cancer cells expressing tumor antigens

3. Pharmacokinetics

Parameter	Detail
Administration	IV infusion over 30 minutes
Dosing	200 mg every 3 weeks or 400 mg every 6 weeks (flat dosing); 2 mg/kg every 3 weeks in children
Elimination half-life	~26 days
Metabolism	Proteolytic degradation (as with all large protein antibodies) - no hepatic CYP450 metabolism
Excretion	No specific organ of elimination
Protein binding	Binds PD-1 receptor; IgG4 does not efficiently activate complement
Drug interactions	No pharmacokinetic drug-drug interactions (not metabolized by CYP enzymes)

4. FDA-Approved Indications

Pembrolizumab holds one of the broadest approval profiles of any oncology drug, currently approved for 18+ different cancers:

Solid Tumors

Cancer Type	Setting	Biomarker Requirement
Melanoma	Advanced/metastatic; adjuvant (stage IIB/IIC/III/IV resected)	None required
NSCLC	First-line (monotherapy or + chemo); second-line post-platinum	PD-L1 TPS ≥1% for monotherapy; TPS ≥50% for 1st-line mono
Head & neck SCC	First-line (+ chemo) or monotherapy; recurrent/metastatic	CPS ≥1 for some indications
Urothelial carcinoma	First-line (cisplatin-ineligible); second-line post-platinum	PD-L1 for first-line
Triple-negative breast cancer	Neoadjuvant + adjuvant; locally advanced/metastatic	PD-L1 CPS ≥10
Cervical cancer	Recurrent/metastatic + chemotherapy	PD-L1 CPS ≥1
Endometrial carcinoma	Advanced/recurrent (+ lenvatinib)	MMR/MSI testing
Gastric/GEJ adenocarcinoma	First-line + chemo; second-line	PD-L1 CPS ≥1
Hepatocellular carcinoma	Previously treated	None
Merkel cell carcinoma	Recurrent/metastatic	None
Renal cell carcinoma	First-line (+ axitinib or lenvatinib)	None
Colorectal cancer	MSI-H/dMMR, 1st-line	MSI-H or dMMR
Esophageal/GEJ	First-line + chemo; second-line	PD-L1 CPS ≥10
TMB-High (≥10 mut/Mb)	Any solid tumor, unresectable/metastatic	TMB ≥10 mutations/megabase
MSI-H/dMMR	Any solid tumor (tissue-agnostic)	MSI-H or dMMR

Hematologic

Classical Hodgkin lymphoma - relapsed/refractory after ≥3 prior lines
Primary mediastinal large B-cell lymphoma - relapsed/refractory

The tissue-agnostic approvals (MSI-H/dMMR and TMB-high) represent a landmark shift: pembrolizumab is the first drug approved based on a tumor's molecular profile rather than its anatomical origin.

5. Key Biomarkers for Patient Selection

Biomarker	Test Method	Role
PD-L1 expression (CPS or TPS)	Immunohistochemistry	Predicts response in NSCLC, gastric, head & neck, cervical, TNBC
MSI-H (Microsatellite Instability-High)	PCR or NGS	Tissue-agnostic approval; strong predictor of response
dMMR (Mismatch Repair Deficient)	IHC for MLH1, MSH2, MSH6, PMS2	Equivalent biomarker to MSI-H
TMB ≥10 mutations/Mb	Next-generation sequencing	Tissue-agnostic approval
BRAF mutation status	Molecular testing	Relevant for sequencing vs. targeted therapy in melanoma

6. Adverse Effects

Pembrolizumab's adverse effects are caused by immune-related adverse events (irAEs) - uncontrolled autoreactivity resulting from PD-1 blockade. These are less frequent than with anti-CTLA-4 agents but can be severe and life-threatening.

Common (>20% of patients)

Fatigue, nausea, decreased appetite, constipation
Cough, dyspnea (in lung cancer patients)
Pruritus, rash
Arthralgia, musculoskeletal pain
Diarrhea

Immune-Related Adverse Events (irAEs) - by organ

System	Adverse Event	Severity
Pulmonary	Pneumonitis	Can be fatal; Grade 3-4 seen in ~3%
GI	Colitis, diarrhea	Common; risk of perforation if severe
Liver	Immune-mediated hepatitis	Monitor LFTs regularly
Endocrine	Hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, type 1 DM	Often permanent (endocrinopathies)
Renal	Nephritis, renal dysfunction	Monitor creatinine
Neurological	Peripheral neuropathy, encephalitis, myasthenia gravis, Guillain-Barré	Rare but serious
Cardiac	Myocarditis (rare, but high mortality if missed)	Rare; check troponin if symptoms
Skin	Severe rash, Stevens-Johnson syndrome, toxic epidermal necrolysis	Rare
Musculoskeletal	Myositis, arthritis	Monitor CK and joint symptoms

7. Management of irAEs

Grade	Action
Grade 1	Continue pembrolizumab; close monitoring; topical/symptomatic treatment
Grade 2	Withhold pembrolizumab; start oral prednisolone 1-2 mg/kg/day; resume when grade ≤1
Grade 3-4	Permanently discontinue; IV methylprednisolone 1-2 mg/kg/day; consider infliximab for steroid-refractory colitis or hepatitis
Endocrinopathies	Usually require lifelong hormone replacement even after drug discontinuation

8. Contraindications & Precautions

Condition	Guidance
Active autoimmune disease	Relative contraindication; may exacerbate (e.g., SLE, IBD, RA)
Organ transplant recipients	Risk of rejection due to immune activation
Pregnancy	Contraindicated - IgG crosses placenta; potential fetal harm
Breastfeeding	Avoid during treatment and for 4 months after last dose
Active infections	Caution; immunostimulation may worsen certain infections
Prior severe irAEs	Carefully re-evaluate risk-benefit before re-challenge

9. Special Considerations

Pseudo-progression: Tumor size may initially appear to increase on imaging due to immune cell infiltration before regression - evaluate with clinical response, not imaging alone. Use iRECIST criteria rather than standard RECIST.

Delayed and durable responses: Responses can appear weeks to months after initiation and may be durable even after discontinuation - some melanoma patients have had responses lasting > 10 years.

Combination strategies:

+ Chemotherapy: Standard in NSCLC, TNBC, gastric cancer, esophageal cancer
+ Ipilimumab (anti-CTLA-4): Synergistic; used in melanoma, NSCLC, RCC, MSI-H colorectal - but higher irAE rates
+ Targeted therapy: Pembrolizumab + lenvatinib (VEGFR inhibitor) in RCC and endometrial cancer
+ Antibody-drug conjugates: Emerging combinations in clinical trials

Immune checkpoint inhibitor class effects: Compared to anti-CTLA-4 agents (ipilimumab), PD-1 inhibitors like pembrolizumab have a more favorable safety profile with lower rates of severe irAEs, while maintaining high efficacy.

10. Monitoring Parameters

Parameter	Frequency
LFTs (AST, ALT, bilirubin)	Before each dose
Thyroid function (TSH, free T4)	Every 3-6 months
Creatinine / renal function	Before each dose
Blood glucose	Periodically
CBC	Periodically
Chest imaging	As clinically indicated (monitor for pneumonitis)
Troponin	If cardiac symptoms arise
CK levels	If myositis suspected

11. Recent Clinical Evidence

A 2023 network meta-analysis (PMID: 37612624) confirmed pembrolizumab + chemotherapy significantly improves pathological complete response (pCR) in high-risk early-stage TNBC compared to chemo alone
A 2024 systematic review (PMID: 38694505) in SCLC showed pembrolizumab combinations provide modest benefit with manageable toxicity in extensive-stage disease
Tissue-agnostic expansion (TMB-high, MSI-H) continues to be validated across tumor types in real-world data

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Illustrated Reviews Pharmacology; Washington Manual of Medical Therapeutics; Goldman-Cecil Medicine; Murray & Nadel's Respiratory Medicine

write briefly 1-2 pages

Based on the comprehensive information already retrieved in our previous conversation, here is the condensed 1-2 page drug profile:

Drug Profile: Pembrolizumab (Keytruda)

Basic Information

Property	Detail
Class	Immune checkpoint inhibitor (anti-PD-1)
Type	Humanized monoclonal IgG4κ antibody
Route	IV infusion only
Trade name	Keytruda
Former name	Lambrolizumab / MK-3475

Mechanism of Action

Under normal physiology, activated T cells upregulate PD-1 (Programmed Death-1) receptors to prevent autoimmunity. Tumor cells exploit this by overexpressing PD-L1, which binds PD-1 on cytotoxic T cells, inducing T-cell exhaustion and immune escape.

Pembrolizumab is a humanized antibody (mouse variable region on a human IgG4 framework) that blocks PD-1 from binding PD-L1/PD-L2. This restores T-cell cytotoxic activity within the tumor microenvironment, increasing TNF-α, IFN-γ, and granzyme B production, enabling immune-mediated tumor destruction.

Mechanism of immune checkpoint inhibitors

Pembrolizumab blocks PD-1 on T lymphocytes; ipilimumab blocks CTLA-4 on the APC side (Lippincott Illustrated Reviews Pharmacology)

Pharmacokinetics

Dose: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks (30-min infusion)
Half-life: ~26 days
Metabolism: Proteolytic degradation - no CYP450 involvement, no pharmacokinetic drug interactions
Elimination: No specific organ of clearance

Approved Indications

Pembrolizumab has one of the broadest approval profiles in oncology, covering 18+ cancers:

Melanoma - advanced/metastatic; adjuvant (stage IIB-IV resected)
NSCLC - first-line monotherapy (PD-L1 ≥50%) or + chemotherapy; second-line post-platinum
Head & neck SCC - recurrent/metastatic ± chemotherapy
Urothelial carcinoma - post-platinum; first-line in cisplatin-ineligible patients
Triple-negative breast cancer - neoadjuvant + adjuvant (+ chemotherapy)
Gastric/GEJ adenocarcinoma - first-line + chemotherapy (CPS ≥1)
Classical Hodgkin lymphoma - relapsed/refractory
Cervical, endometrial, esophageal, hepatocellular, Merkel cell, RCC - various lines
MSI-H / dMMR tumors (any site) - tissue-agnostic approval
TMB-high ≥10 mut/Mb tumors (any site) - tissue-agnostic approval

The tissue-agnostic approvals (based on molecular biomarkers, not tumor origin) were landmark firsts in oncology.

Key Biomarkers

Biomarker	Test	Relevance
PD-L1 (CPS/TPS)	IHC	Required for monotherapy in NSCLC, gastric, HNSCC
MSI-H / dMMR	PCR / IHC	Tissue-agnostic approval; strong predictor of response
TMB ≥10 mut/Mb	Next-gen sequencing	Tissue-agnostic approval

Adverse Effects

Adverse effects are immune-related adverse events (irAEs) from unbridled T-cell activation. Less frequent than anti-CTLA-4 agents but potentially severe:

System	Event
Pulmonary	Pneumonitis (can be fatal)
GI	Colitis, diarrhea
Liver	Immune hepatitis
Endocrine	Hypothyroidism, hyperthyroidism, hypophysitis, adrenal insufficiency, type 1 DM
Renal	Nephritis
Neurological	Peripheral neuropathy, myasthenia gravis, encephalitis
Cardiac	Myocarditis (rare but high mortality)
Skin	Rash, pruritus, rarely SJS/TEN

Common (>20%): Fatigue, nausea, rash, pruritus, arthralgia, diarrhea, decreased appetite.

irAE Management

Grade	Action
Grade 1	Continue; symptomatic treatment
Grade 2	Withhold; oral prednisolone 1-2 mg/kg/day; resume when ≤ Grade 1
Grade 3-4	Permanently discontinue; IV methylprednisolone; infliximab for steroid-refractory colitis/hepatitis
Endocrinopathies	Often require lifelong hormone replacement

Contraindications & Special Precautions

Pregnancy: Contraindicated (IgG crosses placenta)
Active autoimmune disease: Relative contraindication - risk of exacerbation
Organ transplant recipients: Risk of allograft rejection
Pseudo-progression: Tumors may initially enlarge on imaging due to immune infiltration before shrinking - use iRECIST criteria, not standard RECIST
Durable responses: Some melanoma patients have responses lasting >10 years, even after drug discontinuation
Combination use: + ipilimumab (melanoma, NSCLC, RCC) gives synergistic benefit but higher irAE rates; + lenvatinib in RCC and endometrial cancer; + chemotherapy as standard backbone in multiple cancers

Monitoring

TSH/free T4 every 3-6 months; LFTs, creatinine, blood glucose before each cycle; troponin if cardiac symptoms; chest imaging if respiratory symptoms arise.

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Illustrated Reviews Pharmacology; Washington Manual of Medical Therapeutics; Goldman-Cecil Medicine

note on insulin guidelines and its caluclations

Finding Sources

Reading File

I have all the content needed. Here is the comprehensive but concise note:

Insulin: Guidelines and Calculations

1. Types of Insulin Preparations

Type	Examples	Onset	Peak	Duration
Ultra-rapid acting	Faster aspart, lispro-aabc	5-10 min	1-3 hr	3-5 hr
Rapid-acting analogue	Lispro, Aspart, Glulisine	10-20 min (15-30 min)	1-3 hr	3-5 hr
Short-acting (Regular)	Human Regular (U-100, U-500)	30-60 min	2-4 hr	5-8 hr
Intermediate-acting	NPH	2-4 hr	6-10 hr	16-20 hr
Long-acting	Glargine U100, Detemir	1.5-2 hr	Peakless	16-20 hr
Ultra-long-acting	Glargine U300, Degludec	1.5-2 hr	Peakless	>24-42 hr
Premixed	70/30 NPH/Regular, 75/25 lispro mix	Variable	Dual peak	Variable

Prescribing safety note: Always write "units" in full - never abbreviate as "U" (risk of misinterpretation as a zero). Prescribe by full brand name including concentration number (e.g., Lantus U-100).

2. Indications for Insulin Therapy

Type 1 DM

Mandatory for survival - all patients require exogenous insulin from diagnosis

Type 2 DM - initiate insulin when:

Distinction between T1DM and T2DM is unclear
HbA1c ≥ 8.5% at diagnosis
Random blood glucose ≥ 250 mg/dL
Presence of DKA or hyperosmolar hyperglycemic state
Glycemic targets not met with oral agents and/or GLP-1 agonists
Pregnancy with diabetes not controlled by lifestyle/metformin

3. Glycemic Targets

Parameter	General Target	Modified for High-risk/Elderly
HbA1c	< 7.0%	< 8.0% (frail elderly, hypoglycemia-prone)
Fasting BG	80-130 mg/dL	Individualized
Post-prandial BG (2h)	< 180 mg/dL	Individualized
Time in Range (CGM)	> 70% (70-180 mg/dL)
Time below range	< 4% (< 70 mg/dL)

4. Insulin Dose Calculations

Step 1 - Total Daily Dose (TDD)

Clinical Setting	Formula
General starting dose	0.5 units/kg/day
Insulin-naive T2DM (conservative)	0.2-0.3 units/kg/day
Established T1DM (full replacement)	0.5-1.0 units/kg/day
Severe insulin resistance / T2DM	Up to 1.0-2.0 units/kg/day

Example: 70 kg adult → TDD = 0.5 × 70 = 35 units/day

Step 2 - Basal-Bolus Split (50:50 Rule)

Component	Fraction of TDD	Calculation (70 kg, TDD=35)
Basal insulin (glargine/detemir/degludec)	50% of TDD	35 × 0.5 = 17-18 units once daily
Bolus/prandial insulin (rapid-acting)	50% of TDD	17 units ÷ 3 meals = ~5-6 units per meal

If detemir is used as basal: give as BID (split 50% TDD into two doses)

Step 3 - Carbohydrate-to-Insulin Ratio (CIR)

Determines how many grams of carbohydrate are covered by 1 unit of rapid-acting insulin.

Insulin Type	Formula	Example (TDD = 35)
Rapid-acting (lispro, aspart)	500 ÷ TDD	500 ÷ 35 = 1 unit : 14 g carb
Regular insulin	450 ÷ TDD	450 ÷ 35 = 1 unit : 13 g carb

How to use: If a meal contains 56 g carbohydrate and CIR = 1:14 → Bolus dose = 56 ÷ 14 = 4 units

Step 4 - Correction Factor (CF) / Insulin Sensitivity Factor (ISF)

Determines how much 1 unit of rapid-acting insulin will lower blood glucose (in mg/dL).

Insulin Type	Formula	Example (TDD = 35)
Rapid-acting (lispro, aspart)	1800 ÷ TDD	1800 ÷ 35 = ~51 mg/dL per unit
Regular insulin	1500 ÷ TDD	1500 ÷ 35 = ~43 mg/dL per unit

How to use: If pre-meal BG = 220 mg/dL and target is 120 mg/dL: Correction dose = (220 - 120) ÷ 51 = ~2 units

Step 5 - Pre-meal Bolus Dose (Full Calculation)

$$\text{Pre-meal bolus} = \underbrace{\frac{\text{Carb grams}}{\text{CIR}}}{\text{Meal coverage}} + \underbrace{\frac{\text{Actual BG} - \text{Target BG}}{\text{CF}}}{\text{Correction dose}}$$

Worked example (TDD = 35, CIR = 1:14, CF = 51, target BG = 120 mg/dL):

Meal: 70 g carbohydrates; Pre-meal BG = 200 mg/dL

Meal dose = 70 ÷ 14 = 5 units

Correction dose = (200 - 120) ÷ 51 = 1.6 units ≈ 2 units

Total pre-meal dose = 5 + 2 = 7 units

Pediatric Dosing (Harriet Lane Reference)

Component	Formula	Example: 24 kg child
TDD	0.5-1 unit/kg/day (use 0.75 as starting)	0.75 × 24 = 18 units/day
Basal (glargine)	½ TDD once daily	½ × 18 = 9 units daily
Basal (detemir)	½ TDD ÷ BID	½ × 18 ÷ 2 = 4.5 units BID
CIR (rapid-acting)	500 ÷ TDD	500 ÷ 18 = 1 unit : 28 g carb
CIR (regular)	450 ÷ TDD	450 ÷ 18 = 1 unit : 25 g carb
CF (rapid-acting)	1800 ÷ TDD	1800 ÷ 18 = 1 unit drops BG by 100 mg/dL
CF (regular)	1500 ÷ TDD	1500 ÷ 18 = 1 unit drops BG by 83 mg/dL

5. Insulin Regimens

Basal-Bolus (Intensive / Preferred for T1DM and advanced T2DM)

Long-acting insulin once daily (glargine/degludec) or twice daily (detemir) = basal
Rapid-acting insulin before each meal = bolus
Adjust using CIR + CF at each meal
Gold standard for physiologic insulin replacement

Basal-Only (Initial T2DM insulin therapy)

Start with 10 units glargine at bedtime (or 0.1-0.2 units/kg)
Titrate by 2 units every 3 days if fasting BG > 130 mg/dL
Simple; good first step when adding insulin to oral agents

Split-Mixed (Twice Daily)

70/30 premixed insulin - morning and evening
Less flexible; not suitable for carb counting
Used when adherence to basal-bolus is poor

Continuous Subcutaneous Insulin Infusion (CSII - Insulin Pump)

Uses rapid-acting insulin only
Three programmable settings:
- Basal rate - continuous background infusion (units/hr, variable throughout day)
- Bolus/meal - CIR applied at mealtime
- Correction - CF applied when BG above target
Risk: DKA with pump malfunction (no long-acting insulin on board)

6. Titration Guidelines (T2DM Basal Insulin)

Fasting BG (mg/dL)	Dose Adjustment
> 180	Increase by 4 units
140-180	Increase by 2 units
110-139	Increase by 1 unit
80-110	No change (at target)
70-79	Decrease by 2 units
< 70 (hypoglycemia)	Decrease by 10-20%

7. Hypoglycemia - Recognition and Treatment

Severity	BG	Symptoms	Treatment
Mild-Moderate	54-70 mg/dL	Sweating, tremor, palpitations, hunger	Rule of 15: 15 g fast carbs → recheck in 15 min; repeat if still low
Severe	< 54 mg/dL	Confusion, seizure, loss of consciousness	Glucagon IM/SC 1 mg; or IV dextrose 50% (25 mL)

Fast-acting carbohydrate sources (15 g): 4 glucose tablets, 120 mL fruit juice, 150 mL regular soda, 3 teaspoons of sugar.

8. Special Situations

Situation	Recommendation
Illness / surgery	Never omit basal insulin; reduce dose by 20-25%; check BG 2-hourly
Ramadan fasting	Reduce basal by 20-30%; shift meal bolus to Suhoor/Iftar
Pregnancy	Tighter targets (FBG 70-95 mg/dL, 1h post-meal <140 mg/dL); avoid oral agents in T1DM
CKD	Reduce insulin dose (decreased renal clearance of insulin); monitor closely
Perioperative	Reduce basal by 25-50% night before surgery; hold all bolus insulin; target intraoperative BG 140-180 mg/dL
Glucocorticoid-induced hyperglycemia	NPH insulin timed to peak of steroid action is practical; or increase TDD

Sources: Harrison's Principles of Internal Medicine 22e; Goldman-Cecil Medicine International Edition; Harriet Lane Handbook 23e; Goodman & Gilman's Pharmacological Basis of Therapeutics

briefly 1-2 pages

Based on the content already retrieved, here is the condensed 1-2 page note:

Insulin: Guidelines and Calculations

Types of Insulin

Type	Examples	Onset	Peak	Duration
Rapid-acting	Lispro, Aspart, Glulisine	10-20 min	1-3 hr	3-5 hr
Short-acting (Regular)	Human Regular	30-60 min	2-4 hr	5-8 hr
Intermediate	NPH	2-4 hr	6-10 hr	16-20 hr
Long-acting	Glargine, Detemir	1.5-2 hr	Peakless	16-20 hr
Ultra-long	Degludec, Glargine U300	1.5-2 hr	Peakless	>24-42 hr

Always write "units" in full - never "U" (risk of 10-fold dosing error).

Indications to Start Insulin

T1DM - mandatory from diagnosis
T2DM: HbA1c ≥ 8.5% at diagnosis; random BG ≥ 250 mg/dL; DKA; failure of oral agents ± GLP-1 agonist; pregnancy

Glycemic Targets

Parameter	Target
HbA1c	< 7.0% (< 8.0% in frail/elderly)
Fasting BG	80-130 mg/dL
2h Post-prandial	< 180 mg/dL
CGM Time in Range	> 70% (70-180 mg/dL)

Insulin Dose Calculations

Step 1 - Total Daily Dose (TDD)

Patient	Dose
General starting dose	0.5 units/kg/day
Conservative (insulin-naive T2DM)	0.2-0.3 units/kg/day
Full T1DM replacement	0.5-1.0 units/kg/day

Example: 70 kg adult → TDD = 0.5 × 70 = 35 units/day

Step 2 - Basal : Bolus Split (50:50)

Component	Calculation	Example (TDD = 35)
Basal (glargine/degludec)	50% of TDD once daily	17-18 units OD
Prandial (rapid-acting)	50% of TDD ÷ 3 meals	~6 units per meal

Step 3 - Carbohydrate-to-Insulin Ratio (CIR)

How many grams of carbohydrate are covered by 1 unit of insulin

Insulin	Formula	Example (TDD = 35)
Rapid-acting (lispro/aspart)	500 ÷ TDD	500 ÷ 35 = 1 unit : 14 g carb
Regular insulin	450 ÷ TDD	450 ÷ 35 = 1 unit : 13 g carb

Step 4 - Correction Factor (CF) / Insulin Sensitivity Factor

How many mg/dL does 1 unit of insulin drop blood glucose

Insulin	Formula	Example (TDD = 35)
Rapid-acting	1800 ÷ TDD	1800 ÷ 35 = ~51 mg/dL per unit
Regular	1500 ÷ TDD	1500 ÷ 35 = ~43 mg/dL per unit

Step 5 - Full Pre-meal Bolus Formula

$$\text{Bolus} = \frac{\text{Carb grams (meal)}}{\text{CIR}} + \frac{\text{Actual BG} - \text{Target BG}}{\text{CF}}$$

Worked example (TDD=35, CIR=1:14, CF=51, Target BG=120 mg/dL):

Meal: 70 g carbs; Pre-meal BG: 200 mg/dL

Meal dose: 70 ÷ 14 = 5 units

Correction: (200 - 120) ÷ 51 = 2 units

Total = 7 units pre-meal

Pediatric Quick Reference (Harriet Lane)

Component	Formula	Example: 24 kg child
TDD	0.75 units/kg/day	18 units/day
Basal (glargine)	½ TDD once daily	9 units OD
CIR (rapid-acting)	500 ÷ TDD	1 unit : 28 g carb
CF (rapid-acting)	1800 ÷ TDD	1 unit drops BG by 100 mg/dL

Insulin Regimens

Basal-Only (first step in T2DM): Start glargine 10 units at bedtime → titrate by 2 units every 3 days if fasting BG > 130 mg/dL.

Basal-Bolus (T1DM and advanced T2DM): Long-acting OD + rapid-acting before each meal using CIR + CF. Most physiologic approach.

Split-Mixed Twice Daily: 70/30 premixed morning + evening - simpler but inflexible.

Insulin Pump (CSII): Rapid-acting only; programs basal rate (units/hr) + meal bolus (CIR) + correction (CF). Risk of DKA with pump failure.

Basal Insulin Titration (T2DM)

Fasting BG	Adjustment
> 180 mg/dL	Increase by 4 units
140-180 mg/dL	Increase by 2 units
110-139 mg/dL	Increase by 1 unit
80-110 mg/dL	No change (at target)
< 70 mg/dL	Decrease by 10-20%

Hypoglycemia Management

Rule of 15: If BG < 70 mg/dL → give 15 g fast carbs (4 glucose tablets / 120 mL juice) → recheck in 15 min → repeat if still low.

Severe hypoglycemia (unconscious): Glucagon 1 mg IM/SC or IV Dextrose 50% (25 mL bolus).

Special Situations

Situation	Key Adjustment
Surgery / illness	Never omit basal; reduce dose 20-25%; check BG 2-hourly
CKD	Reduce TDD - decreased renal insulin clearance
Pregnancy	Tighter targets: FBG 70-95 mg/dL; 1h post-meal < 140 mg/dL
Steroids	NPH timed to steroid peak; or increase TDD proportionally
Ramadan	Reduce basal 20-30%; shift bolus to Suhoor/Iftar

Sources: Harrison's Principles of Internal Medicine 22e; Goldman-Cecil Medicine; Harriet Lane Handbook 23e

This is a shared conversation. Sign in to Orris to start your own chat.